clinical trial · NCT05487391
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Qilu Pharmaceutical Co., Ltd.·phase3·recruiting·n = 632
Carcinoma, Non-Small-Cell LungQL1706 injectionVinorelbine TartratePaclitaxelCisplatinCarboplatinPemetrexedPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of QL1706 combined with platinum-based chemotherapy versus placebo combined with platinum-based chemotherapy in adjuvant treatment of stage II-IIIB NSCLC without EGFR-sensitizing mutations and ALK fusions after complete surgical resection.The subjects were randomly divided into two groups according to 1:1, with about 316 subjects in the experimental group and the control group.
started
Dec 8, 2022
primary completion
Aug 31, 2027
completion
May 22, 2029
last updated
Oct 15, 2024
official title
QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomized, Double-blind, Multicenter Phase III Clinical Study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol